Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ: VNDA · Real-Time Price · USD
4.030
+0.080 (2.03%)
At close: May 12, 2025, 4:00 PM
4.002
-0.028 (-0.70%)
After-hours: May 12, 2025, 6:52 PM EDT
Vanda Pharmaceuticals Employees
Vanda Pharmaceuticals had 368 employees as of December 31, 2024. The number of employees increased by 165 or 81.28% compared to the previous year.
Employees
368
Change (1Y)
165
Growth (1Y)
81.28%
Revenue / Employee
$547,149
Profits / Employee
-$120,239
Market Cap
237.51M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
VNDA News
- 5 days ago - Vanda Pharmaceuticals Inc. (VNDA) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results - PRNewsWire
- 7 days ago - Vanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026 - PRNewsWire
- 10 days ago - Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025 - PRNewsWire
- 19 days ago - FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA - PRNewsWire
- 5 weeks ago - Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting - PRNewsWire
- 6 weeks ago - Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia - PRNewsWire
- 2 months ago - Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S" - PRNewsWire